Llusern Scientific, a spinout from the University of South Wales, has secured crucial funding.
- The firm is developing rapid diagnostic tests for urinary tract infections (UTIs).
- Support from the Development Bank of Wales accelerates commercial potential.
- Investment is part of a broader effort to back high-growth university spinouts.
- Llusern’s pioneering work could enhance both human and veterinary diagnostics.
Llusern Scientific, a venture originating from the University of South Wales, is taking significant steps in the field of diagnostics by securing a vital six-figure equity investment. The company’s chief focus is on developing a rapid diagnostic test for urinary tract infections, an advancement that could lead to more timely and effective treatment strategies. This investment, provided by the Development Bank of Wales, is set to boost the commercial capabilities of the company, enabling it to bring its innovative solutions to a broader market.
The diagnostic tool, Lodestar DX, is a result of collaborative efforts among experts, including microbiologist Dr. Emma Hayhurst and molecular geneticist Dr. Jeroen Nieuwland. With funding initially garnered through awards from the Longitude Prize and UK innovation agency NESTA, the company aims to offer an affordable method to combat antibiotic resistance. This capability is particularly crucial given the rising prevalence of UTIs and the associated increase in antibiotic-resistant infections.
Llusern Scientific’s diagnostic test significantly reduces the time required to obtain accurate results compared to the traditional urine culture method. The rapid test provides results in only 35 minutes, contrasting sharply with the conventional two-day period. This swift turnaround supports better clinical decisions, potentially reducing unnecessary antibiotic prescriptions and improving patient outcomes. The technology is not limited to human applications; it also holds promise for veterinary use.
The investment from the Development Bank of Wales is part of a strategic initiative to support technology-driven startups with a strong growth trajectory. Harry George from the bank emphasized the role of equity funds in making substantial impacts on such ventures. Similarly, Carl Griffiths noted the importance of nurturing university spinouts beyond the traditional ‘golden triangle’ of London, Cambridge, and Oxford, highlighting Wales as a burgeoning hub for innovation.
Dr. Emma Hayhurst, Chief Executive of Llusern Scientific, pointed out that while their products are commercially available and undergoing real-world evaluations, the pathway to market expansion heavily relies on such financial support. Dr. Hayhurst stated, “Commercializing academic research requires the support of forward-looking funding partners who can provide patient capital.” The company is hopeful that this investment will pave the way for scaling their operations and broadening their market reach.
By securing this equity investment, Llusern Scientific is poised to make notable advancements in diagnostics that may significantly enhance healthcare outcomes.
